Printer Friendly

BUHLMANN Laboratories AG Receives FDA Clearance for Its fCAL[R] turbo Automated, Random Access Calprotectin Test.

Amherst, NH, June 27, 2019 --(PR.com)-- BUHLMANN Laboratories AG is proud to announce it received United States Food and Drug Administration (FDA) 510(k) clearance of its BUHLMANN fCAL[R] turbo. This turbidimetric test was successfully launched all over the world and is now available on the U.S. market. The BUHLMANN fCAL[R] turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin (fCAL), a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. The BUHLMANN fCAL[R] turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings. Utilizing calprotectin for diagnostic testing demands the test be accurate and reproducible over long periods of time which is one of the key characteristics of BUHLMANN fCAL[R] turbo.

The use of a non-invasive inflammation bio-marker such as calprotectin is crucial with the increasing prevalence of gastrointestinal disease and the challenges of traditional treatment pathways. The 2018 clinical guidelines of the American College of Gastroenterology (ACG) strongly recommends fCAL as helpful test that should be considered as an aid to differentiate the presence of IBD from IBS. As a result, major health insurance companies have started covering calprotectin testing (CPT: 83993).

Due to the quality performance and high capacity of BUHLMANN fCAL[R] turbo, this assay can be applied economically in low/mid volume laboratories as well as in very high volume reference labs. Testing turnaround time can be reduced significantly not only compared to the existing ELISA methods but also to other automated, random access calprotectin assays. BUHLMANN fCAL[R] turbo is a real milestone for efficient handling of increasing workloads in the laboratory being the highest throughput calprotectin assay with the fastest time-to-first-result in the U.S. market.

Doug Olson, CEO of BUHLMANN Diagnostics Corp commented, "We are very pleased to launch this robust, high quality assay to assist physicians in evaluating patients in a timely manner and to help laboratories across North America to meet the increasing demand for calprotectin testing. This test provides a high throughput option to our FDA cleared BUHLMANN fCAL[R] ELISA, providing flexibility in testing options. Most importantly, this assay portfolio offers consistency - no matter which assay you choose, results are reliable, accurate, and consistent across the platforms."

In a multi-site clinical study, BUHLMANN fCAL[R] turbo demonstrated excellent precision and reproducibility, while confirming that this test is a valuable diagnostic aid in the diagnosis of IBD and in the discrimination between IBD and IBS.

Visit www.buhlmannlabs.com to learn more about this assay, and overall performance.

About BUHLMANN Laboratories AG

Founded in 1976, BUHLMANN Laboratories AG has continued to focus on growing a product portfolio of in vitro diagnostics and research markets. BUHLMANN is known for outstanding product quality, providing excellent after-sales services, and delivering remarkable scientific innovations. BUHLMANN offers the broadest range of calprotectin products as well as a selection of unique, high-quality assays such as the BUHLMANN Flow CAST[R] product group for Basophil Activation Testing, the BUHLMANN GanglioCombi[TM] products for neuroimmunology, and a variety of Melatonin Assays.

About BUHLMANN Diagnostics Corp (BDC)

BUHLMANN Diagnostics Corp (BDC) is the North American affiliate of BUHLMANN Laboratories AG, the worldwide provider of ELISA kits, RIA kits, lateral flow and flow cytometry assays. Located in Southern New Hampshire, BDC has a highly experienced team who represent a breadth of experience in serving both clinical and basic science research laboratories.

About BUHLMANN Calprotectin Product Line

The calprotectin portfolio consists of the BUHLMANN fCAL[R] ELISA (FDA 510(k) cleared), BUHLMANN fCAL[R] turbo (FDA 510(k) cleared) for testing on most clinical chemistry analyzers (RUO in the US), Quantum Blue[R] fCAL Rapid Test (RUO in the US), and IBDoc[R], the first and only Health Canada Licensed home-testing application for fecal calprotectin in IBD patients (IBDoc[R] not available for sale in the US).

Contact Information:

BUHLMANN Diagnostics Corp

Stacy Smith

844-300-9799

Contact via Email

www.buhlmannlabs.com

info@buhlmannlabs.com

Read the full story here: https://www.pr.com/press-release/788419
COPYRIGHT 2019 PR.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR.com (Press Releases)
Date:Jun 27, 2019
Words:699
Previous Article:Best Western International Endorses FortisPay.
Next Article:National LTC Pharmacy Advocacy Group Asks CMS to Release "Summary Data" on PBM Medicare Spread Pricing Activity.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |